Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of MK-0616 in Healthy Chinese Adults
NCT06814106Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of enlicitide in hypercholesterolemia (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) at 2 months and Number of Participants Who Discontinue the Study Treatment Due to an AE at 2 months. Started Mar 2023; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06814106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06814106.